Merck & Co., Inc. (MRK)

100,18 -1,25 (-1,23 %) À la clôture : 04:00PM EST

Merck & Co., Inc.

126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 67 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Robert M. Davis J.D.	Chairman, President & CEO	6,08M	6,77M	1967
Ms. Caroline Litchfield	Executive VP & CFO	2,8M	S.O.	1969
Ms. Jennifer L. Zachary	Executive VP & General Counsel	2,73M	3,46M	1978
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories	3,44M	S.O.	1962
Mr. Chirfi Guindo	Senior VP & Chief Marketing Officer for Merck Human Health	1,54M	S.O.	1966
Mr. David Michael Williams	Executive VP and Chief Information & Digital Officer	S.O.	S.O.	1969
Mr. Peter Dannenbaum	Vice President of Investor Relations	S.O.	S.O.	S.O.
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	S.O.	S.O.	1982
Ms. Cristal N. Downing	Executive VP and Chief Communications & Public Affairs Officer	S.O.	S.O.	1970
Mr. Steven C. Mizell	Executive VP & Chief Human Resources Officer	S.O.	S.O.	1960

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Merck & Co., Inc. en date du 28 novembre 2023 est 4. Les scores principaux sont Audit : 5; Société : 6; Droits des actionnaires : 3; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.